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Abstract
Background: The HIV epidemic has caused a dramatic increase in tuberculosis (TB) in East and
southern Africa. Several strategies have the potential to reduce the burden of TB in high HIV
prevalence settings, and cost and cost-effectiveness analyses can help to prioritize them when
budget constraints exist. However, published cost and cost-effectiveness studies are limited.
Methods: Our objective was to compare the cost, affordability and cost-effectiveness of seven
strategies for reducing the burden of TB in countries with high HIV prevalence. A compartmental
difference equation model of TB and HIV and recent cost data were used to assess the costs (year
2003 US$ prices) and effects (TB cases averted, deaths averted, DALYs gained) of these strategies
in Kenya during the period 2004–2023.
Results: The three lowest cost and most cost-effective strategies were improving TB cure rates,
improving TB case detection rates, and improving both together. The incremental cost of combined
improvements to case detection and cure was below US$15 million per year (7.5% of year 2000
government health expenditure); the mean cost per DALY gained of these three strategies ranged
from US$18 to US$34. Antiretroviral therapy (ART) had the highest incremental costs, which by
2007 could be as large as total government health expenditures in year 2000. ART could also gain
more DALYs than the other strategies, at a cost per DALY gained of around US$260 to US$530.
Both the costs and effects of treatment for latent tuberculosis infection (TLTI) for HIV+ individuals
were low; the cost per DALY gained ranged from about US$85 to US$370. Averting one HIV
infection for less than US$250 would be as cost-effective as improving TB case detection and cure
rates to WHO target levels.
Conclusion: To reduce the burden of TB in high HIV prevalence settings, the immediate goal
should be to increase TB case detection rates and, to the extent possible, improve TB cure rates,
preferably in combination. Realising the full potential of ART will require substantial new funding
and strengthening of health system capacity so that increased funding can be used effectively.
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There are an estimated 8.8 million new cases of tubercu-
losis (TB) each year, 1.7 million of which result in
death[1]. In East and southern Africa in particular, the
spread of HIV infection has led to a dramatic increase in
TB notifications (Figure 1), and at national level up to
60% of TB patients are co-infected with HIV[2]. The prev-
alence of HIV is now one of the best predictors of national
TB notification rates[1]. Various targets have been estab-
lished for the control of TB and HIV/AIDS. The World
Health Organization (WHO) global targets for TB control
are to detect 70% of smear positive cases and to success-
fully treat 85% of those that are detected by 2005[3]. The
Millennium Development Goals include targets to halve
the year 1990 number of prevalent TB cases and TB deaths
by 2015[4]. More recently the WHO has set a target to
enrol 3 million people on antiretroviral therapy (ART) by
the end of 2005 (the "3-by-5" Initiative); this would
ensure that ART is provided to half of the estimated six
million people who would otherwise be expected to die
from HIV/AIDS in 2004 and 2005[5].
Several strategies have the potential to reduce the burden
of TB in high HIV prevalence settings[6], but where budg-
ets are constrained decisions must be made as to how they
should be prioritized. Reviews of the cost and cost-effec-
tiveness of interventions to control HIV/AIDS[7] and TB
[8,9]show that previous studies are limited in three ways.
First, most studies consider one intervention in one set-
ting; different interventions are not compared in the same
setting. Second, the impact of interventions on the trans-
mission of HIV and TB is considered in only a few studies.
Where transmission has been considered, different mod-
els have been used so that it is difficult to make fair com-
parisons among interventions. Third, the total number of
people that need treatment and care if existing control tar-
gets are to be met, and the affordability of providing such
treatment and care, has received little attention.
In a previous study[10], we used a dynamic model to
compare the impact of a range of strategies on TB inci-
dence and mortality in African countries with a high HIV
prevalence. This model allows for the effect of strategies
on TB transmission to be captured. Here, we use the
model to compare the costs, effects, affordability and cost-
effectiveness of a similar range of strategies, using data for
Outline of the tuberculosis (TB) sub-modelFigur 2
Outline of the tuberculosis (TB) sub-model. In the full model 
(see Methods, and supplementary material of [10]), active TB 
may be infectious or non-infectious, with movement allowed 
from active non-infectious disease to active infectious dis-
ease. An identical sub-model, with different parameter val-
ues, describes those with HIV. Death can occur in any state, 
but death rates are higher for patients with active disease.
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Trends in HIV prevalence and TB notifications in Kisumu Dis-
trict, Kenya Source: personal communication, John Mansoer 
(National TB programme, Kenya) and Laurence Mareum 
(Centers for Disease Control, Kenya).
Table 1: The seven strategies for reducing the burden of TB and 
HIV that were evaluated
1) Improving TB case detection rates so that the WHO target of 
detecting 70% of new smear positive cases is reached in 2005 and 
then sustained
2) Improving TB cure rates so that the WHO target of 85% is reached 
in 2005 and then sustained
3) Improving TB case detection and cure rates simultaneously so that 
both WHO targets are met in 2005 and then sustained
4) Offering a six-month course of treatment for latent TB infection 
(TLTI) to people who are found to be HIV-positive but who do not 
have TB disease
5) TLTI as in strategy 4 but for life
6) Providing antiretroviral treatment (ART) to meet the target set by 
the WHO's "3-by-5" Initiative (with ART considered both for all in 
need and TB patients specifically)
7) Reducing HIV incidence through prevention programmesPage 2 of 14
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Table 2: Unit costs. For normal distributions, the first figure gives the mean and the second the variance. For uniform distributions, 
the two figures give the lower and upper limits.
Cost item Unit Unit Cost 
(2003 US$)
Uncertainty 
Distribution
Reference/assumptions
TB diagnosis costs, existing 
level of case detection
Sputum smear positive case 
detected
101 Normal 
(101, 25)
Nganda et al [11]. For every sputum smear positive case 
detected, assume 10 TB suspects are seen. For each TB 
suspect, assume 3 sputum smears and 1 chest X-ray are 
done, in line with WHO guidelines.
TB diagnosis when case 
detection rate increased to 
70%
Sputum smear positive case 
detected
303 Uniform 
(202, 404)
Recent financial data from Kenya's applications to the 
Global Fund to fight AIDS, TB and Malaria (Pennas T, 
written communication), data submitted to WHO by 
Kenya and other high burden countries [1], and financial 
analyses for the forthcoming second Global Plan to Stop 
TB (2006–2015) being prepared by the Stop TB 
Partnership. These indicate that the average cost per sm+ 
patient detected will increase 2–4 times when activities to 
improve case detection rates to 70% are implemented. 
Further details from authors upon request.
Treatment for sputum 
smear positive TB cases, 
existing cure rate
Patient treated 140 Normal 
(140, 49)
Nganda et al [11].
Treatment for sputum 
smear negative TB cases, 
existing cure rate
Person treated 130 Normal 
(130, 43)
Nganda et al [11].
Treatment for sputum 
smear positive TB cases if 
cure rates improved to 
85%
Person treated 280 Uniform 
(210, 350)
Recent financial data submitted to WHO by Kenya and 
other high burden countries [1], and financial analyses for 
the forthcoming second Global Plan to Stop TB (2006–
2015) being prepared by the Stop TB Partnership. These 
indicate that the average cost per patient treated will 
double when activities to improve cure rates are 
implemented. Further details from authors upon request.
Treatment for sputum 
smear negative TB cases if 
treatment completion rates 
improved to 85%
Person treated 260 Uniform 
(195, 325)
As above for treatment of sputum smear positive cases.
TLTI (6 months) Person treated 32 Uniform 
(27, 37)
Bell et al [19], WHO estimates of population coverage of 
HIV/AIDS interventions [20]. Assume 13% adult 
population accesses VCT each year [20], and that 36% are 
HIV+, 100% are screened for TLTI, 43% start treatment of 
whom 38% complete treatment [21].
TLTI (lifetime) Person year of treatment 64 Uniform 
(54, 74)
As above for TLTI for six months, plus assumption that 
treatment for one year is double the cost of treatment for 
six months.
Treatment for AIDS-
related opportunistic 
infections and palliative 
care in absence of ART
Person year of treatment 211 Uniform 
(167, 323)
Unit costs used for Kenya and other low-income high HIV 
prevalence countries in Africa in recent estimates of the 
resources needed for a comprehensive response to HIV/
AIDS, prepared by UNAIDS (Gutierrez JP, written 
communication). Kenya is in the middle of the range.
Cost of ART for a TB 
patient
Six person months of 
treatment when TB and 
ART overlap
495 Uniform 
(420, 544)
Unit costs used for Kenya and other low-income high HIV 
prevalence countries in Africa in recent estimates of the 
resources needed for a comprehensive response to HIV/
AIDS, prepared by UNAIDS (Gutierrez JP, written 
communication). Kenya is in the middle of the range. 
Drop out rate on ART varies from 5% (optimistic 
scenario) to 20% [10][22].
ART, people without TB Person year of treatment 640 Uniform 
(487, 743)
Sources and assumptions as stated above for ART for TB 
patients.
BMC Public Health 2005, 5:130 http://www.biomedcentral.com/1471-2458/5/130Kenya. As far as possible, strategies are defined in relation
to existing global targets or policy.
Methods
Kenya is a low income country with a per capita income
of US$390 in 2003, and a population of just under 32
million[1]. With almost 200,000 new cases of TB in 2003,
Kenya ranks tenth globally in terms of total TB burden,
and HIV prevalence among adult TB patients aged 15–49
is estimated at 29%[1]. Kenya has been implementing the
internationally recommended TB control strategy known
as DOTS[3] for more than ten years. We chose to focus our
analysis on Kenya because the HIV and TB epidemics are
similar to those in other countries in East Africa, data on
HIV prevalence among women attending antenatal clinics
are available for several districts over the past decade, and
there are good TB notification data for all districts since
1985. There are also recent data on the cost of TB treat-
ment[11], including the costs of initiatives to improve
case detection and cure rates [1] (T. Pennas, written com-
munication).
We considered seven strategies for reducing the burden of
TB in Kenya and similar high HIV prevalence settings
(Table 1). All strategies were assessed over the period
2004–2023, and compared with a "baseline" scenario in
which interventions continue at their 2003 levels, which
we take to be nationwide implementation of the DOTS
strategy, a 50% TB case detection rate, a 70% TB cure rate,
and no provision of antiretroviral treatment (ART) or
treatment of latent TB infection (TLTI). While some peo-
ple in Kenya were receiving ART or TLTI in 2003, no pre-
cise data are available and the numbers were small[5].
We used a dynamic model of TB progression with a statis-
tical model of HIV prevalence to assess the effectiveness of
the different strategies. Figure 2 illustrates the general
structure of the model, which was written in Visual Basic.
A full description is available in the supplementary mate-
rial for our previous study[10], including the parameter
values and data sources used.
The TB model was designed so that the impact of strate-
gies on TB transmission can be captured, and consists of
two sub-models. The first describes the transitions
between states for individuals who are not infected with
HIV, or who are in the early stages of HIV (stages 1 and 2
of the WHO staging system[12,13]. The second describes
transitions for those in the later stages of HIV. Active TB
can arise when a) those who acquire a new TB infection
develop progressive primary disease within 1 year or b)
those who acquire a new TB infection enter a latent state,
and may later develop TB by reactivation or reinfection. A
proportion of individuals who are latently infected can
develop TB within 1 year of reinfection. Active TB may be
infectious or non-infectious.
A separate HIV model was used to estimate the number of
new (incident) cases of HIV that occur in each time step
(one time step is equal to one quarter of a year). After
approximately 4 years (i.e. the time lag between HIV infec-
tion and late-stage HIV, defined here as WHO stage
3[12,14]), this number of individuals moves from the first
TB sub-model (i.e. the sub-model that describes individu-
als without HIV infection and individuals in the early
stages of HIV infection) to the corresponding state (either
uninfected or latently infected with TB) in the second TB
sub-model (i.e. the sub-model that describes individuals
in the later stages of HIV infection). In the later stages of
HIV infection, co-infection with TB leads to a greatly
increased risk of developing TB, although a smaller frac-
tion of those with active TB become infectious. Individu-
als with late-stage HIV infection (WHO stages 3 and
above) also have a higher death rate, with and without
active TB.
Estimates of HIV incidence were derived from estimates of
the time dependent HIV prevalence and the survival func-
tion for HIV-infected people[15]. Estimates of HIV preva-
lence were obtained by fitting the available data on HIV
prevalence over time to a double logistic function (see
supplementary material to [10]). This allows the initial
rate of increase, the peak prevalence, the final steady-state
prevalence and the rate of convergence to the steady-state
to be varied. Data from the US Bureau of Census show
that in 1999 the prevalence of HIV infection among
women attending antenatal clinics (ANC) in Kenya had
reached about 14%[16]. Analysis of the most recent ANC
data suggests that HIV prevalence had fallen to just over
9% by 2003[17]. A recent demographic and health survey
indicates that HIV prevalence could have been as low as
7% in 2002[18]. Our main set of analyses assumed that
the HIV prevalence was 14% in adults in 1999 and that it
stabilises at this level. As part of uncertainty analyses, we
also considered the consequences of assuming that HIV
prevalence stabilizes at 7%.
The earlier version of our model[10] was designed to pro-
duce estimates of the number of TB cases and deaths that
occur when different control strategies are implemented
(and thus the number of TB cases and deaths that are
averted by strategies that improve on the baseline sce-
nario). For this study, we extended the model in three
ways. First, we included as model outputs the number of
TB patients detected and treated each year, the number of
person years of ART and TLTI, the number of person years
of treatment for AIDS-related opportunistic infections and
the number of person years of palliative care for people
with AIDS. We assumed that without ART people spendPage 4 of 14
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the last two years in this stage they have AIDS. We
assumed that all HIV+ TB patients are eligible for ART, in
line with WHO guidelines[14], and that overall 50% of
those with AIDS receive ART, in line with the aim of the
"3 by 5" Initiative.
Table 3: Summary of major cost, effectiveness and cost-effectiveness results for the strategies assessed, 2004–2023*
Total annual costs (US$ millions)
Intervention TB Treatment AIDS Treatment, 
excluding ART
ART or TLTI Total Annual 
Costs
Total Incremental 
Cost vs. Baseline 
Scenario
Baseline scenario† 18.5 63.7 0.0 82.2 N/A
Improve TB Detection Rate 27.4 66.7 0.0 94.1 11.9
Improve TB Cure Rate 25.1 64.7 0.0 89.8 7.6
Improve TB Cure Rate and Case Detection Rate 26.9 67.3 0.0 94.2 12.0
TLTI, 6 months 18.3 63.7 0.7 82.8 0.6
TLTI, Lifetime 18.0 63.6 8.0 89.7 7.5
ART, 50% dropout rate 18.2 62.1 153 233 151
ART, 20% dropout rate 17.5 58.8 348 424 342
ART, 5% dropout rate 16.2 52.1 656 725 642
ART to TB patients 18.4 62.5 71.7 152.6 70.5
Total annual effects‡
Intervention DALYs Gained vs. Baseline Scenario Deaths Averted vs. Baseline 
Scenario
TB Cases Averted 
vs. Baseline Scenario
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 551,184 26,015 59,436
Improve TB Cure Rate 220,939 10,087 43,378
Improve TB Cure Rate and Case Detection Rate 676,748 31,769 97,795
TLTI, 6 months 7,366 549 2,119
TLTI, Lifetime 20,178 2,075 5,480
ART, 50% dropout rate 585,232 7,390 4,025
ART, 20% dropout rate 834,071 23,794 12,183
ART, 5% dropout rate 1,205,912 56,872 27,446
ART to TB patients 152,604 5,089 1,126
Cost-effectiveness (US$)§
Intervention Cost per DALY Gained Cost per Death Averted Cost per TB Case 
Averted
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 21.6 458 201
Improve TB Cure Rate 34.3 752 175
Improve TB Cure Rate and Case Detection Rate 17.8 379 123
TLTI, 6 months 84.7 1,136 294
TLTI, Lifetime 373 3,630 1,374
ART, 50% dropout rate 258 20,461 37,569
ART, 20% dropout rate 410 14,370 28,064
ART, 5% dropout rate 533 11,294 23,403
ART to TB patients 462 13,846 62,578
*Total incremental costs and total incremental effects are average figures across the 20 year period that was considered. Trends over time are 
shown in the figures.
† The baseline scenario is defined as TB treatment only, with a case detection rate of 50% and a cure rate of 70%, and no TLTI or ART.
‡ In the baseline scenario there are an estimated 774,000 deaths per year and an estimated 225,000 TB cases per year
§Calculated as incremental costs divided by total incremental effects. Numbers are sometimes different to the total costs divided by total effects 
shown in the table due to rounding.Page 5 of 14
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patient or per person year, as appropriate) in year 2003
US$ of detecting and treating TB, providing ART, provid-
ing a six month course of TLTI, providing treatment for
AIDS-related opportunistic infections, and providing pal-
liative care for people with AIDS. The unit costs, assump-
tions and sources of data are shown in Table 2[10,11,19-
22]. We combined the number of patients or person years
with unit costs to estimate total annual costs, and com-
pared this with estimated annual government health
expenditure in Kenya, which in 2000 was approximately
US$200 million[23]. Costs incurred in future years were
discounted at 3% per annum[24,25]. We only included
costs to the health system because few data are available
on the costs that are borne by patients and their house-
holds, particularly during TLTI and ART.
Finally, we added calculation of the number of disability-
adjusted life years (DALYs) gained to the measures of
effectiveness that the model was initially designed to con-
sider (i.e. TB cases prevented and TB deaths averted). The
calculation of DALYs gained was important because the
health gains from ART and HIV prevention strategies are
broader than prevented TB cases and deaths; thus, fair
comparisons among the seven strategies that we consid-
ered required a more generic measure of effectiveness. We
assumed that averting a TB death would lead to a gain of
4 DALYs in an HIV-positive person and 24 DALYs in an
HIV-negative person [26-30]. We assumed that one DALY
is gained for each year that a person takes ART plus one
DALY for each year that the person survives after default-
ing from ART. We assumed that for each HIV infection
averted, 22 DALYs are gained[7,26,27]. DALYs gained in
future years were discounted at 3% per annum.
We considered each intervention separately, using Monte
Carlo simulations to obtain probability distributions and
95% confidence intervals for model outputs (see [10] for
further details). Total costs and effects are incremental
costs and effects, i.e. the net increase or decrease in costs
or change in effects as compared to the baseline scenario.
Cost-effectiveness was calculated as the net change in
Numbers receiving treatment for different strategies: (a) number of TB patients treated; (b) number of person years of AIDS-related opportunistic infection treatment and palliative care (not including ART); (c) number of person years of TLTI; (d) number of perso  years of ARTFigur  3
Numbers receiving treatment for different strategies: (a) number of TB patients treated; (b) number of person years of AIDS-
related opportunistic infection treatment and palliative care (not including ART); (c) number of person years of TLTI; (d) 
number of person years of ART. CDR = Case detection rate. CR = Cure rate. 6 m = 6 months. ART 50%, ART 20% and ART 
5% mean ART with a 50%, 20% and 5% drop out rate, respectively. ART TB is ART for TB patients only, at a dropout rate of 
20%. (k) means thousands.Page 6 of 14
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pared to the baseline scenario; we report the cost per TB
case averted, per death averted and per DALY gained.
The population level impact on HIV of interventions
aimed at reducing HIV incidence is difficult to quantify,
because the effect of HIV prevention interventions on HIV
incidence has seldom been quantified. The few rand-
omized controlled trials that have been done lead to con-
tradictory conclusions[31,32]. We therefore estimated the
cost per HIV infection averted at which the cost-effective-
ness of HIV prevention matched that of the other strate-
gies being considered.
Results
A summary of the major cost, effectiveness and cost-effec-
tiveness results is provided in Table 3.
In the baseline scenario (i.e. 50% TB case detection rate
and 70% cure rate), the number of TB patients treated
steadily increases (Figure 3a). The trend is similar when
TLTI is provided or if ART is available with a drop out rate
of 50% or 20% per year. Providing ART only has a notice-
able long-term impact on the number of TB patients
treated if the drop out rate is as low as 5% per year.
Improving TB cure rates, and simultaneously improving
TB case detection and cure rates, both cause a substantial
reduction in the number of TB patients treated. Improving
TB case detection has less impact, but by 2012 it reduces
the number of TB patients treated compared to the base-
line scenario.
The number of person-years of treatment for AIDS-related
opportunistic infections and palliative care for people
with AIDS (i.e. AIDS-related treatment and care other
than ART) steadily increases in the baseline scenario (Fig-
ure 3b). Only the provision of ART leads to a substantial
reduction (Figure 3b), provided the drop out rate per year
is relatively low.
If TLTI is provided for six months, the number of people
receiving TLTI stabilizes at about 25,000 per year; if it is
provided for life the number reaches 150,000 after 10
years and almost 300,000 after 20 years (Figure 3c). If ART
is given to 50% of those in need and the drop out rate is
20%, the number of people receiving ART will reach
700,000 by 2024 (Figure 3d). However, if the drop out
rate is 5% per year the number of people receiving ART
will reach almost 2 million by 2024.
The incremental costs (i.e. the net increase in cost com-
pared to the baseline scenario) of the different strategies
are shown in Figure 4. The additional annual cost of
improving TB cure rates rises to US$7.5 million ten years
after improvements are first implemented. Beyond 2013
costs increase more slowly, reaching a peak of US$8.6 mil-
lion after twenty years. The additional annual cost of
improving TB case detection rates increases sharply to
US$12 million after ten years and then remains fairly
steady (between US$12 million and US$14 million) for
the rest of the twenty years. Improving TB case detection
and cure rates simultaneously is initially more costly than
implementing either strategy independently, with a peak
incremental cost of US$12 million in 2013. From then
onwards, additional annual costs decrease year-on-year as
transmission and hence the number of TB cases are
reduced, falling to just under US$10 million per year after
20 years. Providing ART is considerably more expensive
than the other strategies. With a drop out rate of 20% per
year, the incremental cost reaches $200 million per year in
Disability adjusted life years (DALYs) gained by each strategyFigure 5
Disability adjusted life years (DALYs) gained by each strategy. 
See Figure 3 text for label definitions.
Incremental costs compared to baseline scenario for each strategyFigure 4
Incremental costs compared to baseline scenario for each 
strategy. Black line represents estimated total government 
health expenditure in Kenya in the year 2000. See Figure 3 
text for label definitions.Page 7 of 14
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2000); with a drop out rate of 5% per year the incremental
cost reaches US$200 million in 2006 and US$1 billion in
2023. With a drop-out rate of 50% per year, the total cost
reaches the level of government health expenditures in
year 2000 by around 2009. The incremental cost of pro-
viding TLTI is much lower even if it is offered for life.
Figure 5 shows the incremental effectiveness of each strat-
egy (i.e. the net increase or decrease in DALYs gained com-
pared to the baseline scenario). Providing ART with a drop
out rate of 5% per year is the most effective strategy and
could gain an extra 2.3 million DALYs each year by 2024.
Providing ART with a drop out rate of 20% per year gains
about 1.3 million extra DALYs per year by 2024. In the
long run, simultaneous improvement of TB case detection
and cure rates gains slightly more DALYs per year than
providing ART with a 20% per year drop out rate,
although ART averts more when averaged over the twenty
years. TLTI gains a comparatively small number of extra
DALYs.
Figure 6 shows the cost-effectiveness of the different inter-
ventions. Improving TB case detection costs US$22 per
DALY gained, and improving cure rates costs US$34 per
DALY gained. Doing both simultaneously costs US$18
per DALY gained. ART costs around US$260 to US$530
per DALY gained, depending on the drop-out rate and the
type of patients considered (people enrolled as TB
patients only, or all people enrolled on ART). To gain a
DALY by providing TLTI for 6 months, at US$85, is more
than four times as costly as improving TB cure rates and
detection rates simultaneously and TLTI for life has a sim-
ilar cost to ART, at US$373 per DALY gained. The cost per
death averted is less than US$800 for the TB interventions,
while providing ART costs around US$11,000 to
US$20,000 to avert one death. Providing TLTI for 6
months does rather better at about US$1,100 to avert one
death. The cost per TB case averted is also small for
improvements in TB case detection and cure rates (about
US$ 200 per case averted or less), while providing ART
costs about US$30,000 to US$60,000 per TB case averted.
Figure 7 shows the impact of the various interventions on
TB incidence and death rates. Providing ART or TLTI has
little impact on TB incidence or deaths. Improving TB cure
rates leads to a slow but steady decline in TB incidence
and deaths, improving case detection rates does rather
better and doing both simultaneously leads to TB cases
and deaths declining by almost 50% between 2004 and
2023. However, compared with estimated TB incidence
and death rates of, respectively, 104 and 49 per 100,000
population in 1990 (the baseline year to which the Mil-
lennium Development Goals refer), the decline in both
cases and deaths would be much smaller.
Taking the costs of other interventions averaged over ten
years, averting one HIV infection for less than US$4,000
to US$5,000 would be as cost effective as ART and avert-
ing one HIV infection for less than US$250 would be as
cost effective as improving TB case detection and cure
simultaneously to WHO target levels.
Full uncertainty analysis results are available from authors
upon request but the major results over time periods of 10
years and for HIV prevalence stabilising at 7% are pro-
duced in Tables 4 and 5. In brief, these show that the rel-
ative cost-effectiveness of the different strategies is similar
when a time period of ten years is considered, and when
HIV prevalence stabilizes at 7%. The pattern is also similar
when the rate of progress towards targets is 25% and 50%
of the level considered in this article (data not shown).
Cost-effectiveness of each strategy, with 95% confidence intervalsFigur  6
Cost-effectiveness of each strategy, with 95% confidence 
intervals. See Figure 3 text for label definitions.Page 8 of 14
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that cost-effectiveness improves for strategies that have an
important impact on TB transmission when a longer time
period is considered (for example, the cost per DALY
gained by simultaneously improving TB case detection
and cure rates is US$18 when a time period of 20 years is
considered, and US$37 when a time period of 10 years is
considered). The second is that when HIV prevalence is
assumed to stabilize at 7%, the numbers receiving TLTI
and ART are reduced by about 50%, as would be expected.
As a consequence, improving the TB case detection rate
averts as many DALYs as ART with a 5% annual dropout
rate, and simultaneous improvement in TB case detection
and cure rates gains the largest number of DALYs.
Discussion
This study suggests that the most cost-effective and afford-
able strategies for controlling TB in Kenya are to further
increase TB case detection and cure rates, preferably in
combination. Providing ART at the levels proposed in the
WHO's "3-by-5" initiative has limited impact on TB inci-
dence and death rates, but because it prevents deaths from
both TB and non-TB related causes it could gain more
DALYs than would be achieved by reaching global TB con-
trol targets if the drop out rate is low. High compliance
with ART is clearly desirable, and as the cumulative
number of people on ART builds up will require invest-
ment that is substantial in the context of existing levels of
government health expenditure. In contrast, TLTI has rel-
atively low total costs and effects. Similar findings are
likely to apply to other countries with HIV and TB epi-
demics that are at a similar stage to those in Kenya i.e.
countries where rapid increases in HIV and TB incidence
have already occurred, where income levels and hence
unit costs are comparable, and where HIV prevalence is
now stable or starting to fall.
The effectiveness of improvements in TB case detection
and cure rates in terms of DALYs gained may appear sur-
prisingly large, especially compared to ART. One explana-
tion is that improvements in TB case detection and cure
rates result in DALYs being gained among both HIV-posi-
tive and HIV-negative individuals. With HIV prevalence
among TB patients about 30%, an average of 18 DALYs
are gained for every TB death that is averted. Under our
assumptions this is equivalent to the gain from 18 years of
ART. The second explanation is that improvements in TB
control have a major effect on TB transmission.
ART has a relatively small impact on TB outcomes because
we have assumed, in line with the WHO's "3-by-5" Initia-
tive, that the people in need of ART are those HIV-positive
people who, without access to treatment, would be
expected to die within two years. To have a major impact
on TB incidence and deaths, ART would need to be given
earlier in the course of HIV-infection[15]. The effective-
ness of TLTI is limited by coverage of HIV testing and
counselling services. We have assumed that people will
only be given TLTI if their HIV status is known and active
TB has been excluded. Recent pilot projects suggest that
there is a relatively low level of uptake and comple-
tion[21]. However, providing TLTI for just 6 months
appears to be relatively cost-effective. The limited addi-
tional benefits and large costs of providing TLTI for life
suggest that this should not be promoted as a public
health intervention.
Effect of each strategy on TB incidence and TB deaths: (a) TB incidence per 100,000 population; (b) TB deaths per 100,000 populationFig re 7
Effect of each strategy on TB incidence and TB deaths: (a) TB incidence per 100,000 population; (b) TB deaths per 100,000 
population. See Figure 3 text for label definitions.Page 9 of 14
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grammes cost US$11 to US$2,000 per HIV infection pre-
vented[7]. Alternatively, if we assume that the risk of HIV
infection per sex act varies from about 1 per 100 sexual
encounters among those at highest risk to 1 per 1,000 sex-
ual encounters among those at medium risk[33] and that
the cost of providing a condom is US$0.25, then the cost
of averting one HIV infection by making condoms availa-
Table 4: Summary of major cost, effectiveness and cost-effectiveness results for the strategies assessed, 2004–2013*
Total annual costs (US$ millions)
Intervention TB Treatment AIDS Treatment, 
excluding ART
ART or TLTI Total Annual 
Costs
Total Incremental 
Cost vs. Baseline 
Scenario
Baseline scenario† 16.3 61.8 0.0 78.2 N/A
Improve TB Detection Rate 26.3 63.1 0.0 89.4 11.2
Improve TB Cure Rate 23.4 62.1 0.0 85.5 7.3
Improve TB Cure Rate and Case Detection Rate 28.3 63.3 0.0 91.7 13.5
TLTI, 6 months 16.2 61.8 0.646 78.7 0.6
TLTI, Lifetime 16.1 61.8 4.13 82.1 3.9
ART, 50% dropout rate 15.9 59.0 143 217 139
ART, 20% dropout rate 15.2 54.5 277 346 268
ART, 5% dropout rate 14.4 49.6 409 473 395
ART to TB patients 16.2 60.6 47.45 124 46.1
Total annual effects‡
Intervention DALYs Gained vs. Baseline 
Scenario
Deaths Averted vs. Baseline 
Scenario
TB Cases Averted vs. 
Baseline Scenario
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 307,158 19,034 34,193
Improve TB Cure Rate 85,223 5,005 24,447
Improve TB Cure Rate and Case Detection Rate 362,939 22,356 58,268
TLTI, 6 months 2,924 346 1,244
TLTI, Lifetime 5,952 836 2,535
ART, 50% dropout rate 444,020 14,313 5,698
ART, 20% dropout rate 578,943 36,105 13,930
ART, 5% dropout rate 706,577 59,075 22,405
ART to TB patients 86,835 5,714 1,045
Cost-effectiveness (US$)§
Intervention Cost per DALY Gained Cost per Death Averted Cost per TB Case 
Averted
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 37 591 329
Improve TB Cure Rate 86 1,470 300
Improve TB Cure Rate and Case Detection Rate 37 604 232
TLTI, 6 months 190 1,610 447
TLTI, Lifetime 655 4,660 1,540
ART, 50% dropout rate 314 9,730 24,400
ART, 20% dropout rate 463 7,420 19,200
ART, 5% dropout rate 559 6,690 17,600
ART to TB patients 531 8,070 44,100
*Total incremental costs and total incremental effects are average figures across the 10 year period that was considered. Trends over time are 
shown in the figures.
† The baseline situation is defined as TB treatment only, with a case detection rate of 50% and a cure rate of 70%, and no TLTI or ART.
‡ In the baseline scenario there are an estimated 725,000 deaths per year and an estimated 198,000 TB cases per year
§Calculated as incremental costs divided by total incremental effects. Numbers are sometimes different to the total costs divided by total effects 
shown in the table due to rounding.Page 10 of 14
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Table 5: Summary of major cost, effectiveness and cost-effectiveness results for the strategies assessed if the predicted HIV prevalence 
is halved, 2004–2023*
Total annual costs (US$ millions)
Intervention TB Treatment AIDS Treatment, 
excluding ART
ART or TLTI Total Annual 
Costs
Total Incremental 
Cost vs. Baseline 
Scenario
Baseline scenario† 17.6 32.3 0.0 49.8 N/A
Improve TB Detection Rate 24.3 34.2 0.0 58.4 8.6
Improve TB Cure Rate 23.8 32.9 0.0 56.7 6.8
Improve TB Cure Rate and Case Detection Rate 23.5 34.6 0.0 58.1 8.3
TLTI, 6 months 17.5 32.3 0.401 50.2 0.3
TLTI, Lifetime 17.3 32.3 4.43 54.0 4.2
ART, 50% dropout rate 17.3 31.4 80.3 129.0 79.2
ART, 20% dropout rate 16.7 29.6 180 226.8 176.9
ART, 5% dropout rate 15.7 26.2 337 378.7 328.9
ART to TB patients 17.5 31.5 45.84 94.8 45.0
Total annual effects‡
Intervention DALYs Gained vs. Baseline Scenario Deaths Averted vs. Baseline 
Scenario
TB Cases Averted vs. 
Baseline Scenario
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 662,609 28,344 66,677
Improve TB Cure Rate 268,347 11,258 45,780
Improve TB Cure Rate and Case Detection Rate 816,465 34,826 106,872
TLTI, 6 months 6,036 367 1,473
TLTI, Lifetime 16,193 1,120 3,801
ART, 50% dropout rate 311,693 4,566 3,496
ART, 20% dropout rate 453,396 14,214 10,485
ART, 5% dropout rate 662,802 32,773 23,189
ART to TB patients 100,602 3,513 1,360
Cost-effectiveness (US$)§
Intervention Cost per DALY Gained Cost per Death Averted Cost per TB Case 
Averted
Baseline scenario† N/A N/A N/A
Improve TB Detection Rate 13 303 129
Improve TB Cure Rate 25 606 149
Improve TB Cure Rate and Case Detection Rate 10 237 77
TLTI, 6 months 52 862 215
TLTI, Lifetime 257 3,710 1,090
ART, 50% dropout rate 254 17,300 22,700
ART, 20% dropout rate 390 12,400 16,900
ART, 5% dropout rate 496 10,000 14,200
ART to TB patients 447 12,800 33,100
*Total incremental costs and total incremental effects are average figures across the 20 year period that was considered. Trends over time are 
shown in the figures.
† The baseline situation is defined as TB treatment only, with a case detection rate of 50% and a cure rate of 70%, and no TLTI or ART.
‡ In the baseline scenario there are an estimated 648,000 deaths per year and an estimated 224,000 TB cases per year
§Calculated as incremental costs divided by total incremental effects. Numbers are sometimes different to the total costs divided by total effects 
shown in the table due to rounding.
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Although these estimates cover a rather broad range, com-
parison with our threshold analyses suggest that HIV pre-
vention programmes can compete favourably with the
other strategies that we considered.
This analysis has some limitations. First, the benefits of
ART could have been under or over-estimated. Under-esti-
mation is possible because the epidemiological model
does not allow for the impact that ART may have on HIV
transmission or TB cure rates. ART may reduce transmis-
sion when it is started at relatively high CD4+ cell counts,
as in developed countries[34]. Current guidelines for
resource-poor settings such as Kenya recommend starting
ART later at lower CD4+ cell counts[14], at which there is
no evidence that ART will reduce overall levels of trans-
mission. Nevertheless, ART may offer opportunities to
strengthen prevention efforts quite apart from its impact
on lowering the viral load in people who access treat-
ment[35], and it is also possible that it will increase TB
cure rates by improving the general health of TB patients.
Overestimation is possible because we assumed that one
DALY would be gained for each year of ART. This is equiv-
alent to assuming that there is no morbidity associated
with ART. In practice, some people on ART will experience
side-effects.
Second, the costs of providing ART are difficult to assess.
In particular, the non-drug costs that we used are based on
the strategy developed for achievement of the "3-by-5"
goal [5,36], which places emphasis on community-based
care and limited use of CD4 count and viral load tests.
Drug costs are already low and may not fall much further,
but other costs could have been underestimated because
there is little evidence about the costs of providing ART in
practice and on a massive scale in poor countries. More
documentation of the costs of existing ART programmes,
especially those that are now being scaled up nationwide,
is needed. If ARV drug costs are assumed to be zero (as
opposed to around US$140 per year), our analyses sug-
gest that the cost per DALY gained by ART would be about
US$320 to US$420.
Third, few data have been published on the life expect-
ancy of patients who default from ART. We have assumed
that following default a person is at the same stage in the
natural history of HIV as someone entering late-stage HIV
(WHO stage 3). This means that those given ART effec-
tively pass through stage 3 twice: first before being given
ART; second following default from ART. During stage 3,
they are more susceptible to TB, and therefore individuals
that are HIV-positive and given ART have an increased risk
of TB for longer than HIV-positive individuals not given
ART. There are insufficient data available to confirm
whether this is an appropriate assumption, but this may
explain why the reduction in the number of TB cases
under the ART strategy described in this study is even
lower than that predicted elsewhere[15].
Fourth, we only assessed the impact of implementing one
strategy at a time. It will be of importance to explore the
combined effect of TB control and the provision of ART,
which together are likely to have a bigger impact on both
TB and HIV.
Fifth, there is as yet limited evidence about the costs of
improving TB case detection and cure rates in practice,
once coverage of the DOTS strategy has reached 100%. We
combined data about the existing cost per patient detected
and treated[11] with available data on the factor by which
the average cost per patient detected and treated will
change as case detection and cure rates are improved.
While we have used estimates of the factor by which aver-
age costs change, our results are consistent with the pro-
posed total increase in Kenya's TB control budget
included in recent data submitted to WHO and in the
country's recent funding applications to the GFATM. Our
results suggest an increase in annual costs of around
US$12 million, compared to the proposed budgetary
increase of US$11.5 million. Evidence about the relation-
ship between increased spending and improvements in
case detection and cure rates should be collected in the
next few years in Kenya and other countries, to assist plan-
ning and budgeting for improved TB control and so that
the relationship between costs and improved case detec-
tion and cure rates can be better understood.
Our findings support current efforts in Kenya to increase
TB case detection rates and improve cure rates. Recent
analyses suggest that this is feasible through measures
such as expanding DOTS implementation beyond the
35% of health facilities in which it is currently available,
expanding DOTS implementation into the private sector,
extending existing training to nurses who are the first con-
tact with the health system for many TB suspects and who
play a major role in delivery of TB treatment, and through
implementation of advocacy, communication and social
mobilization activities (C. Hanson, personal communica-
tion; T. Pennas, written communication).
Conclusion
Overall, our study suggests that the priority for national
TB control programmes in high HIV prevalence settings
should be to concentrate first on improving TB cure and
case detection rates. This should be highly cost-effective,
affordable in the context of existing national health budg-
ets, and could make an important contribution to
achievement of the Millennium Development Goal tar-
gets related to TB. Realising the full potential of ART will
require substantial new funding and strengthening ofPage 12 of 14
(page number not for citation purposes)
BMC Public Health 2005, 5:130 http://www.biomedcentral.com/1471-2458/5/130health system capacity so that increased funding can be
used effectively.
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